Influenza Virus Transmission
Respiratory Tract Epithelial Cells Before And After Infection With Influenza A Virus
Symptoms Of Influenza
Complications Of Influenza
Estimated Excess Deaths Attributable To Influenza Among Adults, 1968-1978
Anti-Viral Therapy Why Neuraminidase Inhibitors?
Targeting The Influenza Neuraminidase
Structure-Based Drug Design
Inhibition Of Neuraminidase Enzymes
Zanamivir Is A Potent Inhibitor Of Influenza Virus Replication In Vitro
Influenza Virus: No Evidence Of Resistance To Zanamivir In Clinical Programme
Representative Distribution Of Zanamivir After Inhalation From DiskhalerTM
Very High Local Concentrations Of Zanamivir In Lung After Inhalation
Clinical Programme
European (Phase III) Treatment Study
Patient Assessments
Primary Endpoint
PPT Slide
Demography
Median Time To Alleviation Of Symptoms Influenza-Positive
Median Symptom Severity Scores (Days 1?14). Influenza-Positive
Influenza-Positive: Symptom Severity Percent Change From Baseline (Approx. 24 hours)
Median Time To Return To Normal Activities Influenza-Positive
Median Days To Alleviation Of Symptoms (Phase III Studies) Influenza-Positive
Purpose Of Pooled Analysis
Phase II And III Zanamivir Treatment Studies
Median Time To Alleviation Of Symptoms
Median Time To Alleviation Of Symptoms High-Risk Influenza-Positive
Return To Normal Activities Pooled Analysis
Antibiotic Use For Complications Pooled Analysis
Australian Patient Survey
Influenza Symptoms In Patients Consulting Because Of Influenza (n=1408)
Speed Of Onset Of Symptom Relief (% Patients) : Australian Patient Survey
Time Taken To Resume Normal Activities (% Patients) : Australian Patient Survey
Zanamivir Has A Similar Adverse Event Profile to Placebo in Clinical Trials
Reported Respiratory Adverse Events
Safety
Conclusions
Inhaled Zanamivir For Preventing Transmission Of Influenza In Families
Zanamivir Prophylaxis Study Primary Endpoint
Zanamivir Prophylaxis Study - Conclusions
Email: webmaster@sbimc-bvikm.org
Home Page: http://www.sbimc.org/sbimc-bvikm-slides.htm